Table 4 Odds ratios and 95% CI for incident hypertension of subjects according to baseline serum uric acid in the cohort study

Model 1

Men/Women (mg/dL)

Total

N

Odds ratio (95% CI)

p-value

N

Odds ratio (95% CI)

p-value

SUA-1

0.6–5.2/1.7–3.9

109

31/8

1.0

–

61/9

1.0

–

SUA-2

5.3–5.8/4.0–4.4

91

27/7

1.01 (0.32–3.14)

0.994

49/8

1.11 (0.40–3.08)

0.846

SUA-3

5.9–6.4/4.5–5.2

97

27/10

1.44 (0.50–4.16)

0.505

45/15

2.26 (0.91–5.62)

0.080

SUA-4

6.5–9.2/5.3–7.8

94

26/10

1.49 (0.51–4.33)

0.463

39/19

3.30 (1.36–8.03)

0.008

Continuous variable

391

111/35

1.17 (0.83–1.64)

0.372

194/51

1.54 (1.16–2.05)

0.003

Model 2

Men/Women (mg/dL)

Total

N

Odds ratio (95% CI)

p-value

N

Odds ratio (95% CI)

p-value

SUA-1

0.6–5.2/1.7–3.9

109

31/8

1.0

–

61/9

1.0

–

SUA-2

5.3–5.8/4.0–4.4

91

27/7

1.01 (0.32–3.18)

0.981

49/8

1.03 (0.37–2.89)

0.959

SUA-3

5.9–6.4/4.5–5.2

97

27/10

1.44 (0.49–4.19)

0.507

45/15

2.11 (0.84–5.29)

0.113

SUA-4

6.5–9.2/5.3–7.8

94

26/10

1.61 (0.55–4.73)

0.389

39/19

2.97 (1.20–7.35)

0.018

Continuous variable

391

111/35

1.19 (0.85–1.68)

0.313

194/51

1.50 (1.12–2.00)

0.006

Model 3

Men/Women (mg/dL)

Total

N

Odds ratio (95% CI)

p-value

N

Odds ratio (95% CI)

p-value

SUA-1

0.6–5.2/1.7–3.9

109

31/8

1.0

–

61/9

1.0

–

SUA-2

5.3–5.8/4.0–4.4

91

27/7

0.87 (0.25–3.09)

0.833

49/8

1.25 (0.41–3.77)

0.692

SUA-3

5.9–6.4/4.5–5.2

97

27/10

1.59 (0.47–5.36)

0.456

45/15

2.23 (0.81–6.11)

0.119

SUA-4

6.5–9.2/5.3–7.8

94

26/10

1.33 (0.37–4.85)

0.662

39/19

3.84 (1.36–10.8)

0.011

Continuous variable

391

111/35

1.16 (0.78–1.74)

0.468

194/51

1.59 (1.14–2.23)

0.007